검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | High Dose Chemotherapy |
Overview Company | Celgene |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarkers are critical to predict which patients will require treatment escalation |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refractory classical Hodgkin lymphoma: a case report and literature review.. Most patients with classical Hodgkin lymphoma (cHL) can achieve long-term survival with frontline combination chemotherapy and radiation therapy, but approximately 10%-30% of patients will develop relapsed/refractory (R/R) disease… |
Clinical Primary efficacy | ORR 29% |
Clinical ORR | 29% |
Clinical Result source | ClinicalTrials.gov NCT01182415 |
Clinical Data Tier / Score | A · 51 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (14일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | High Dose Chemotherapy |
Overview Company | Celgene |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarkers are critical to predict which patients will require treatment escalation |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refractory classical Hodgkin lymphoma: a case report and literature review.. Most patients with classical Hodgkin lymphoma (cHL) can achieve long-term survival with frontline combination chemotherapy and radiation therapy, but approximately 10%-30% of patients will develop relapsed/refractory (R/R) disease… |
Clinical Primary efficacy | ORR 29% |
Clinical ORR | 29% |
Clinical Result source | ClinicalTrials.gov NCT01182415 |
Clinical Data Tier / Score | A · 51 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (14일 전 · 갱신 권장) |
추천 비교
추천 비교